Top Story

Time-dependent treatment may lead to better CML outcomes

March 6, 2015

Switching from imatinib to nilotinib at the right time may be a beneficial treatment strategy for some patients with chronic phase chronic myeloid leukemia, according to results of a study conducted in Australia.

Prior research showed use of imatinib (Gleevec, Novartis) conferred excellent outcomes as front-line treatment for chronic phase CML. In the IRIS trial, 85% of patients remained alive at 8 years; however, 45% ultimately discontinued imatinib because of intolerance, resistance to the drug or disease progression.

SARAH Study completes enrollment for HCC trial, results expected in 2016

March 6, 2015
The SARAH Study, a large French study of patients with advanced, inoperable hepatocellular carcinoma, has completed enrollment with more than 400 patients and expects…
Maura M. Zylla, MD In the Journals

Intracardiac thrombi rates lower with dabigatran, rivaroxaban, compared with phenprocoumon

March 6, 2015
The prevalence of intracardiac thrombi was lower in high-risk patients with atrial fibrillation and flutter treated with direct oral anticoagulants compared with…
FDA approvalsDrug Pipeline

FDA approves first biosimilar product

March 6, 2015
The FDA today announced the approval of filgrastim-sndz, the first biosimilar product approved in the United States.“Biosimilars will provide access to important…
In the Journals

Hospital type, patient age influence treatment of newly diagnosed myelodysplastic syndrome

March 6, 2015
Patients treated for recently diagnosed myelodysplastic syndrome at major academic institutions received more aggressive treatment than those treated at community…
More News Headlines »
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
thumbnail for video 4040847621001

MET targeting, PD-L1/PD-1 inhibition highlight recent developments in genitourinary oncology

February 11, 2015
Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, president of Levine Cancer Institute at Carolinas HealthCare System and…
More »
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »